KalVista to Showcase Sebetralstat Phase 3 Results at AAAAI 2024

KalVista Pharmaceuticals, a company dedicated to developing oral, small molecule protease inhibitors, has had several abstracts accepted for presentation at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. Scheduled to take place from February 23 to 26 in Washington, DC, the meeting will feature a series of presentations on February 24, focusing on various aspects of Hereditary Angioedema (HAE) treatment and patient experiences.

The topics to be discussed include the characteristics of HAE attacks among those on long-term prophylaxis, patient perceptions and barriers related to delayed on-demand treatment, and the impact of anxiety on treatment for HAE attacks. Additionally, the presentations will cover the negative consequences of delayed on-demand treatment, the influence of on-demand treatment on the quality of life for HAE patients, and the perspectives of patients on prophylactic treatment.

Furthermore, there will be a late-breaking presentation on February 25, detailing the results of the double-blind, placebo-controlled Phase 3 KONFIDENT Trial for sebetralstat, an oral, on-demand treatment for HAE attacks. This trial's positive phase 3 data was disclosed by KalVista in February 2024, and the company plans to submit a new drug application for sebetralstat to the U.S. FDA in the first half of the year, with additional filings for approval in Europe and Japan expected later in 2024.

KalVista's commitment to advancing treatments for HAE and other diseases is also evident in their oral Factor XIIa inhibitor program, which is aimed at providing a new generation of therapies to improve patient outcomes. The company's focus on diseases with significant unmet needs underscores its dedication to making a difference in the lives of those affected by such conditions.

KalVista Pharmaceuticals is a clinical-stage pharmaceutical company with a mission to discover, develop, and commercialize innovative treatments for diseases that currently lack effective solutions.